Genomic Vision

Financial Information for the Third Quarter of 2018

Regulatory News:

Genomic Vision (Paris:GV) (FR0011799907 – GV), a company specialized in the development of in-vitro diagnostic (IVD) tests for the early detection of cancers and genetic diseases and applications for life sciences research (LSR), today announced its revenue and cash position¹ at September 30, 2018.

Revenue for the third quarter and first 9 months of 2018

			9 months								3rd quarter
In thousands of euros – IFRS			2018		2017		∆				2018			2017		∆
Revenue from Quest Diagnostics R&D			356		225		+58%				206			75		+175%
Sales of products & services			655		1,104		-41%				194			437		-56%
of which: life sciences research (LSR)			485		751		-35%				166			161		+3%
of which: in-vitro diagnostics (IVD)			170		353		-52%				28			276		-90%
Total revenue from sales			1,011		1,329		-24%				400			512		-22%
Other revenue			1,130		885		+28%				258			189		+37%
Total revenue from activity			2,141		2,214		+0.03%				658			701		-6%

During the third quarter of 2018, sales of products and services were down 56% at €194 thousand, including: